Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.31 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.30 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4035986 | 0.84 | SYK (0.38) | SYKMCHR1MAPK7DDR1HRH3 | |
| SCHEMBL4034708 | 0.83 | SYK (0.39) | SYKMAPK7DDR1HRH3 | |
| SCHEMBL3429086 | 0.65 | ESR2 (0.36) | — | |
| SCHEMBL3429416 | 0.64 | F2RL3 (0.36) | — | |
| SCHEMBL3280568 | 0.64 | SRC (0.43) | — | |
| SCHEMBL3177791 | 0.64 | ESR2 (0.42) | — | |
| SCHEMBL6463306 | 0.63 | HDAC6 (0.49) | — | |
| SCHEMBL3177738 | 0.62 | TNF (0.39) | — | |
| SCHEMBL4038428 | 0.62 | RAF1 (0.41) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL4033450 | 0.61 | LMNA (0.37) | SYKPDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054662-A1 | Quinazoline derivatives as antitumor agents | ERBB2, ERBB3, ABL1 | SYK 318/4885MCHR1 2603/4885KCNH2 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.